7th October 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

CDSCO initiates investigation on Gambia Children deaths case linked with Maiden Pharma

Central Drugs Standard Control Organization has joined hands with the concerned state regulatory bodies to investigate upon the information shared by WHO. The cough and cold syrups manufactured by Maiden Pharmaceuticals is allegedly responsible for the death of 66 Children in the Gambia.

Glenmark Pharma launches drug for Type 2 Diabetes Mellitus in India

Glenmark Pharma announced that it has become India’s first company to launch Thiazolidinedione Lobeglitazone for Type 2 DM in Adults. In addition, Indians have a high number of Type 2 diabetes patients who have “insulin resistance” for which their drug LOBG is a good option.

Dolo controversy reminds regulatory bodies to revise the pharma marketing practices

The use of unethical means to promote a brand is against the Uniform Code for Pharmaceutical Marketing Practices that is responsible for regulation of marketing. But unlike Doctor’s Hippocratic Oath, it is voluntary and thus occassionally exploited by Pharma industries.

5 Samples taken from Pharmaceutical facility in Baddi

DCA (Drug Control Administration) drew five samples of liquid formulations manufactured using ethylene glycol from Maiden Pharmaceuticals Baddi unit as a precautionary measure after its Sonipat facility’s ‘substandard’ formulations killed 66 children in Gambia.

WHO reported Pharma Firm's Drugs found to be 'substandard' in Kerela lab tests

The Delhi-based Pharma Company Maiden Pharmaceuticals over the counter painkiller drug and Type-2 Diabetes Prescription drug were found to be ‘substandard’ quality during lab tests in Kerela, that too almost five times in the last nine months.

Zydus receives final approval from US FDA for Brivaracetam tablets

Zydus was the first applicant to file a substantially complete Abbreviated New Drug Application with a paragraph IV certification. It has received a final nod from US regulatory authority to manufacture and market Brivaracetam tablets USP 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg.

Natco Pharma Ltd launches Chlorantraniliprole pesticide containing products in India

The company has announced the kick-off of two Chlorantraniliprole (CTPR) pesticide formulated combination products with the brand names NATVOL (CTPR 8.8% + Thiamethoxam 17.5% SC); and NATLIGO (CTPR 9.3% + Lambda-cyhalothrin 4.6% ZC).

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.
Start chat
1
Need Help?
PharmaState Academy
Hello, how can we help you?